# Vial Health Technology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vial-health-technology

- Industry: Software
- Headquarters: San Francisco, US
- Website: www.vial.com
- Total disclosed funding: $67M
- Latest round: Series B (Nov 30, 2022)
- Investors on record: 3

## About

Based in California, US, and founded in 2020 by Andrew Brackin, and Simon Burns, Vial Health Technology is a clinical trial infrastructure company that offers technology solutions to help achieve faster resents in biotech trials in creating novel drugs. In November 2022, Vial Health Technology, Inc. raised USD B funding led by new investor General Catalyst Partners, with participation from other new investors BoxGroup and Byers Capital. The firm offers its services to clinical trials in oncology, dermatology, ophthalmology, gastroenterology, neurology, and cardiology. 

Vial CRO facilitates faster and more efficient clinical trials in a variety of therapeutic areas by providing clinical operators with an intuitive Electronic Source and powerful CRA tooling. To accelerate the clinical development of novel medicines, the platform powers trials from site startup to database lock.

The company intends to use the November 2022 funding to support its clinical trials.

## Funding rounds

- Series B, Nov 30, 2022, $67M — General Catalyst Partners, BoxGroup, Byers Capital

## Investors

- General Catalyst Partners (https://capitalatlas.ai/funds/general-catalyst-partners) — Series B
- BoxGroup (https://capitalatlas.ai/funds/boxgroup) — Series B
- Byers Capital (https://capitalatlas.ai/funds/byers-capital) — Series B